The epidermal growth factor receptor as a target for colorectal cancer therapy.
about
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayThermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerKRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasisExploiting novel molecular targets in gastrointestinal cancers.Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancerIdentification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.Computational design of binding proteins to EGFR domain II.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.Role of novel targeted therapies in the clinic.Recent developments in colorectal cancer treatment by monoclonal antibodies.Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal CancerTranslational up-regulation of Aurora-A in EGFR-overexpressed cancerA multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.Cetuximab in the treatment of patients with colorectal cancer.KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry.Higher expression of Caveolin-1 inhibits human small cell lung cancer (SCLC) apoptosis in vitro.Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.
P2860
Q24675853-232D0681-C05C-4D5C-8775-E151E8194D6AQ27648835-357C6D39-4975-4567-B407-2305ADF8ABD2Q28077545-6A817A02-BC24-40FD-A66D-440278816FD0Q33519564-F720DF07-4A38-4A4E-8761-0D198F3A97CDQ34382777-F9CE93F9-CC95-49F5-8BEA-15C8553D05E9Q34636336-9948372A-9CD8-48C9-8CE3-E2D840F88A8BQ35030421-0465C2BF-5DB4-488B-B199-32E4240E378CQ35141923-2C2F86F1-C280-48B6-BFC5-E35030477B51Q35584153-50EFF6C3-36E4-4107-9C20-D97DE982262BQ35587176-0E553598-5DBC-4144-9F86-3388AB8711A1Q36071752-7812B86B-45C1-46E9-B280-212A534B0DF9Q36321184-67C2436D-4C9F-49A5-A45F-E666ECE6D3A5Q36523502-E2B978AA-28C6-42AE-93B6-BB988282E704Q36616926-F49901DC-F55D-4CFE-9423-E896C7A595C5Q36627254-248073A6-0E97-4024-8A0A-798B2686925FQ37001330-8D6BD679-0B10-4EE3-BFCC-DFD43D598FE8Q37148157-687EDB75-979F-4AB9-9EE0-884E13D652E7Q37310991-1F8AD7AA-BD1C-4518-81FE-30F24204083FQ37396252-B02D5870-FDE9-4F56-8A85-5D62CF27B559Q37697540-3EE07F63-E729-4806-9A68-61E80296A4C6Q37873948-80C9BD8B-3E94-497E-9DFF-F63B7F48413EQ39225749-8D11CB76-B66E-4387-82EA-C75B84AF5ADFQ39303797-D0801009-E2D8-432C-89A6-62DDB141550CQ39356412-C5F23E1E-2CA1-4674-A5BE-5DA667D899FEQ40255826-B4CDA393-723B-4EEC-8BC0-DDD02195EFCEQ43622554-E6812B40-CB71-4376-8EF9-02BAE36F8BA7Q45203079-A5DB0FDE-E21B-43AC-AB60-3DD9B41A1F8AQ47190620-62D11F9E-9E4B-4658-953F-892265B479F1Q55460041-983B9B7C-90B9-4E0C-9190-B1746AA46576
P2860
The epidermal growth factor receptor as a target for colorectal cancer therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@ast
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@en
type
label
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@ast
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@en
prefLabel
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@ast
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@en
P1433
P1476
The epidermal growth factor receptor as a target for colorectal cancer therapy.
@en
P2093
A Craig Lockhart
Jordan D Berlin
P356
10.1053/J.SEMINONCOL.2004.09.036
P577
2005-02-01T00:00:00Z